Markets
BNTX

BioNTech Boosts FY25 Revenue Outlook - Update

November 03, 2025 — 07:13 am EST

Written by RTTNews.com for RTTNews->

(RTTNews) - While reporting financial results for the third quarter on Monday, immunotherapy company Biopharmaceutical New Technologies or BioNTech SE (BNTX) said it now expects revenues for the full-year 2025 to be between 2.6 billion and 2.8 billion euros, up from the prior forecast range between 1.7 billion to 2.2 billion euros.

For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Tags

Markets
RTTNews
Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.
More articles by this source->

Stocks mentioned

BNTX

More Related Articles

Info icon

This data feed is not available at this time.

Data is currently not available

  • •

Sign up for the TradeTalks newsletter to receive your weekly dose of trading news, trends and education. Delivered Wednesdays.